期刊
PHARMACEUTICS
卷 12, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics12100999
关键词
half-life; drug delivery; ocular; subcutaneous; intravenous; oral; mucosal; biologics; proteins; peptides
资金
- UK National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology
- Helen Hamlyn Trust in memory of Paul Hamlyn
- Michael and Ilse Katz Foundation
- Moorfields Eye Charity
- Santen Pharmaceuticals Inc, Co.
- EPSRC [EP/L01646X/1]
Proteins and peptides have emerged in recent years to treat a wide range of multifaceted diseases such as cancer, diabetes and inflammation. The emergence of polypeptides has yielded advancements in the fields of biopharmaceutical production and formulation. Polypeptides often display poor pharmacokinetics, limited permeability across biological barriers, suboptimal biodistribution, and some proclivity for immunogenicity. Frequent administration of polypeptides is generally required to maintain adequate therapeutic levels, which can limit efficacy and compliance while increasing adverse reactions. Many strategies to increase the duration of action of therapeutic polypeptides have been described with many clinical products having been developed. This review describes approaches to optimise polypeptide delivery organised by the commonly used routes of administration. Future innovations in formulation may hold the key to the continued successful development of proteins and peptides with optimal clinical properties.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据